Maryse Lapeyre-Mestre

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5026345/publications.pdf

Version: 2024-02-01

362 papers 10,372 citations

43973 48 h-index 71532 76 g-index

483 all docs 483 docs citations

483 times ranked

10727 citing authors

#	Article	IF	Citations
1	Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. British Journal of Clinical Pharmacology, 2011, 72, 905-908.	1.1	309
2	French health insurance databases: What interest for medical research? Revue De Medecine Interne, 2015, 36, 411-417.	0.6	273
3	Adverse drug reactions and off-label drug use in paediatric outpatients. British Journal of Clinical Pharmacology, 2002, 54, 665-670.	1.1	263
4	Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood, 2014, 124, 3308-3315.	0.6	248
5	Prescription of drugs during pregnancy in France. Lancet, The, 2000, 356, 1735-1736.	6.3	199
6	Cannabis Use: Signal of Increasing Risk of Serious Cardiovascular Disorders. Journal of the American Heart Association, 2014, 3, e000638.	1.6	199
7	Off-Label Prescribing of Antipsychotics in Adults, Children and Elderly Individuals: A Systematic Review of Recent Prescription Trends. Current Pharmaceutical Design, 2015, 21, 3280-3297.	0.9	153
8	Anxious and depressive symptoms in Parkinson's disease: The French crossâ€sectionnal DoPaMiP study. Movement Disorders, 2010, 25, 157-166.	2.2	136
9	Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. BMJ: British Medical Journal, 2011, 343, d3908-d3908.	2.4	127
10	Hospitalizations because of Adverse Drug Reactions in Elderly Patients Admitted through the Emergency Department. Drugs and Aging, 2009, 26, 475-482.	1.3	112
11	Serious and Non-Serious Infections in Non-Splenectomized Adults Treated for Persistent or Chronic Primary Immune Thrombocytopenia: Effect of Treatments and Protection of Vaccines. Results of the French Nationwide Faith Study. Blood, 2015, 126, 9-9.	0.6	110
12	Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenetics and Genomics, 2012, 22, 784-795.	0.7	108
13	A study of salivary secretion in Parkinson's disease. Clinical Neuropharmacology, 1999, 22, 213-5.	0.2	104
14	What is the Current Knowledge About the Cardiovascular Risk for Users of Cannabis-Based Products? A Systematic Review. Current Atherosclerosis Reports, 2017, 19, 26.	2.0	97
15	Severe necrotizing soft-tissue infections and nonsteroidal anti-inflammatory drugs. Clinical and Experimental Dermatology, 2008, 33, 249-255.	0.6	95
16	Cannabisâ€related hospitalizations: unexpected serious events identified through hospital databases. British Journal of Clinical Pharmacology, 2011, 71, 758-765.	1.1	91
17	Pharmacovigilance forÂevaluating adverse drug reactions: value, organization, andÂmethods. Joint Bone Spine, 2006, 73, 629-632.	0.8	90
18	Sleep Attacks and Antiparkinsonian Drugs: A Pilot Prospective Pharmacoepidemiologic Study. Clinical Neuropharmacology, 2001, 24, 181-183.	0.2	85

#	Article	lF	Citations
19	Exercise training for managing behavioral and psychological symptoms in people with dementia: A systematic review and meta-analysis. Ageing Research Reviews, 2015, 24, 274-285.	5.0	82
20	Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study. European Journal of Clinical Pharmacology, 2011, 67, 1053-1059.	0.8	79
21	Assessment of Abuse Potential of Benzodiazepines from a Prescription Database Using â€~Doctor Shopping' as an Indicator. CNS Drugs, 2010, 24, 611-620.	2.7	77
22	Trends in use of antipsychotics in elderly patients with dementia: Impact of national safety warnings. European Neuropsychopharmacology, 2014, 24, 95-104.	0.3	76
23	Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies. Fundamental and Clinical Pharmacology, 2016, 30, 616-624.	1.0	74
24	Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults. Journal of Thrombosis and Haemostasis, 2018, 16, 1830-1842.	1.9	71
25	Immediate―and delayedâ€ŧype allergic reactions to amide local anesthetics: clinical features and skin testing. Pharmacoepidemiology and Drug Safety, 2009, 18, 595-601.	0.9	70
26	Pharmacological and clinical evidences on the potential for abuse and dependence of propofol: a review of the literature. Fundamental and Clinical Pharmacology, 2007, 21, 459-466.	1.0	69
27	Gender differences in adverse drug reactions: analysis of spontaneous reports to a Regional Pharmacovigilance Centre in France. Fundamental and Clinical Pharmacology, 2002, 16, 343-346.	1.0	68
28	Cancer Risk of Anti-TNF- $\hat{l}\pm$ at Recommended Doses in Adult Rheumatoid Arthritis: A Meta-Analysis with Intention to Treat and per Protocol Analyses. PLoS ONE, 2012, 7, e48991.	1.1	68
29	Potentially inappropriate medication use among patients with Alzheimer disease in the REAL.FR cohort: be aware of atropinic and benzodiazepine drugs!. European Journal of Clinical Pharmacology, 2013, 69, 1589-1597.	0.8	68
30	Off-Label Prescribing in Pediatric Outpatients. Pediatrics, 2015, 135, 49-58.	1.0	67
31	Newly diagnosed immune thrombocytopenia adults: Clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort. American Journal of Hematology, 2017, 92, 493-500.	2.0	67
32	Survey of Forged Prescriptions to Investigate Risk of Psychoactive Medications Abuse in France. Drug Safety, 2007, 30, 265-276.	1.4	66
33	Misuse and Dependence on Non-Prescription Codeine Analgesics or Sedative H1 Antihistamines by Adults: A Cross-Sectional Investigation in France. PLoS ONE, 2013, 8, e76499.	1.1	66
34	Patterns of gabapentin and pregabalin use and misuse: Results of a populationâ€based cohort study in France. British Journal of Clinical Pharmacology, 2019, 85, 1260-1269.	1.1	64
35	Assessing the Feasibility of Using an Adverse Drug Reaction Preventability Scale in Clinical Practice. Drug Safety, 2002, 25, 1035-1044.	1.4	62
36	Drug related falls: a study in the French Pharmacovigilance database. Pharmacoepidemiology and Drug Safety, 2005, 14, 11-16.	0.9	62

#	Article	IF	CITATIONS
37	Case ascertainment and estimated incidence of drugâ€induced longâ€QT syndrome: study in Southwest France. British Journal of Clinical Pharmacology, 2008, 66, 386-395.	1.1	62
38	Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals. British Journal of Clinical Pharmacology, 2000, 50, 479-484.	1.1	61
39	Buprenorphine in pregnant opioid-dependent women: first results of a prospective study. Addiction, 2004, 99, 209-214.	1.7	60
40	Utilisation and Safety of Low Molecular Weight Heparins. Drug Safety, 2003, 26, 197-207.	1,4	59
41	Benzodiazepines and risk of death: Results from two large cohort studies in France and UK. European Neuropsychopharmacology, 2015, 25, 1566-1577.	0.3	57
42	What is pharmacoepidemiology? Definition, methods, interest and clinical applications. Therapie, 2019, 74, 169-174.	0.6	57
43	Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database. BMC Psychiatry, 2020, 20, 308.	1.1	57
44	Potentially Inappropriate Drug Prescribing and Associated Factors in Nursing Homes. Journal of the American Medical Directors Association, 2014, 15, 850.e1-850.e9.	1,2	56
45	Addictovigilance contribution during COVID-19 epidemic and lockdown in France. Therapie, 2020, 75, 343-354.	0.6	54
46	Perception of the risk of adverse drug reactions: differences between health professionals and non health professionals. British Journal of Clinical Pharmacology, 2002, 54, 433-436.	1.1	53
47	Guillain-Barré Syndrome and Adjuvanted Pandemic Influenza A (H1N1) 2009 Vaccines: A Multinational Self-Controlled Case Series in Europe. PLoS ONE, 2014, 9, e82222.	1.1	53
48	Analgesic drug consumption increases after knee arthroplasty: A pharmacoepidemiological study investigating postoperative pain. Pain, 2014, 155, 1339-1345.	2.0	53
49	Mortality Associated With Time in and Out of Buprenorphine Treatment in French Office-Based General Practice: A 7-Year Cohort Study. Annals of Family Medicine, 2017, 15, 355-358.	0.9	52
50	Risk of Serious Extrapyramidal Symptoms in Patients With Parkinson's Disease Receiving Antidepressant Drugs: A Pharmacoepidemiologic Study Comparing Serotonin Reuptake Inhibitors and Other Antidepressant Drugs. Clinical Neuropharmacology, 2003, 26, 142-145.	0.2	51
51	Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: A pharmacoepidemiological-pharmacodynamic study in VigiBase. European Neuropsychopharmacology, 2015, 25, 1556-1565.	0.3	51
52	Potential underuse of analgesics for recognized pain in nursing home residents with dementia: A cross-sectional study. Pain, 2013, 154, 2427-2431.	2.0	50
53	Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: A systematic review and meta-analysis. Autoimmunity Reviews, 2016, 15, 203-209.	2.5	50
54	Adverse Drug Reactions to Gabapentin and Pregabalin. Drug Safety, 2013, 36, 55-62.	1.4	49

#	Article	IF	CITATIONS
55	Doctor shopping reveals geographical variations in opioid abuse. Pain Physician, 2013, 16, 89-100.	0.3	49
56	Nonsteroidal anti-inflammatory drug-induced liver injury: a case-control study in primary care. Fundamental and Clinical Pharmacology, 2004, 18, 201-206.	1.0	48
57	Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database. Rheumatology, 2014, 53, 1864-1871.	0.9	47
58	Exposure to Atropinic Drugs and Frailty Status. Journal of the American Medical Directors Association, 2015, 16, 253-257.	1.2	47
59	Drug Interactions with Cholinesterase Inhibitors. Drug Safety, 2007, 30, 1063-1071.	1.4	46
60	Adverse drug reactions associated with the use of NSAIDs: a case/noncase analysis of spontaneous reports from the French pharmacovigilance database 2002–2006. Fundamental and Clinical Pharmacology, 2013, 27, 223-230.	1.0	46
61	A multicentric individually-tailored controlled trial of education and professional support to nursing home staff: Research protocol and baseline data of the IQUARE study. Journal of Nutrition, Health and Aging, 2013, 17, 173-178.	1.5	45
62	Prevalence and Associations of the Use of Proton-Pump Inhibitors in Nursing Homes: A Cross-Sectional Study. Journal of the American Medical Directors Association, 2013, 14, 265-269.	1.2	45
63	Non-steroidal anti-inflammatory drug-related hepatic damage in France and Spain: analysis from national spontaneous reporting systems. Fundamental and Clinical Pharmacology, 2006, 20, 391-395.	1.0	44
64	Influence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant Escherichia coli in a university hospital. Journal of Antimicrobial Chemotherapy, 2010, 65, 2650-2657.	1.3	44
65	Searching for a Polypharmacy Threshold Associated With Frailty. Journal of the American Medical Directors Association, 2015, 16, 259-261.	1.2	44
66	Medical prescriptions falsified by the patients: a 12â€year national monitoring to assess prescription drug diversion. Fundamental and Clinical Pharmacology, 2018, 32, 306-322.	1.0	44
67	Genomewide Association Study of Statinâ€Induced Myopathy in Patients Recruited Using the <scp>UK</scp> Clinical Practice Research Datalink. Clinical Pharmacology and Therapeutics, 2019, 106, 1353-1361.	2.3	44
68	Falsified or forged medical prescriptions as an indicator of pharmacodependence: A pilot study. European Journal of Clinical Pharmacology, 1997, 52, 37-39.	0.8	43
69	Adverse Drug Reactions to Selegiline[colon] A Review of the French Pharmacovigilance Database. Clinical Neuropharmacology, 2000, 23, 271-275.	0.2	43
70	Estimated magnitude of diversion and abuse of opioids relative to benzodiazepines in France. Drug and Alcohol Dependence, 2012, 126, 13-20.	1.6	42
71	Microtubule-Driven Stress Granule Dynamics Regulate Inhibitory Immune Checkpoint Expression in T Cells. Cell Reports, 2019, 26, 94-107.e7.	2.9	42
72	Comparison of chronic analgesic drugs prevalence in Parkinson's disease, other chronic diseases and the general population. Pain, 2009, 141, 14-18.	2.0	41

#	Article	IF	CITATIONS
73	Statins and Erectile Dysfunction. Drug Safety, 2009, 32, 591-597.	1.4	41
74	Evaluation of Abuse and Dependence on Drugs Used for Self-Medication. Drug Safety, 2009, 32, 859-873.	1.4	41
75	Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study. European Journal of Clinical Pharmacology, 2012, 68, 1533-1540.	0.8	40
76	Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and) Tj ETQq0 0 0 rgBT Clinical Pharmacology, 2004, 60, 673-677.	/Overlock 0.8	10 Tf 50 62 39
77	Slowâ€release oral morphine for opioid maintenance treatment: a systematic review. British Journal of Clinical Pharmacology, 2011, 71, 832-843.	1.1	39
78	Evidence of clonazepam abuse liability: results of the tools developed by the French Centers for Evaluation and Information on Pharmacodependence (CEIP) network. Fundamental and Clinical Pharmacology, 2011, 25, 633-641.	1.0	39
79	Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity. American Journal of Hematology, 2014, 89, 41-46.	2.0	39
80	Using a capture–recapture method to assess the frequency of adverse drug reactions in a French university hospital. British Journal of Clinical Pharmacology, 2006, 62, 225-231.	1.1	38
81	Efficacy and safety of biologics in relapsing polychondritis: a French national multicentre study. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212705.	0.5	38
82	Death related to a recreational abuse of propofol at therapeutic dose range. British Journal of Anaesthesia, 2006, 97, 268.	1.5	37
83	Drugs and dilated cardiomyopathies: a case/noncase study in the French PharmacoVigilance Database. British Journal of Clinical Pharmacology, 2010, 69, 287-294.	1.1	37
84	Baclofen for alcohol dependence in France: Incidence of treated patients and prescription patternsâ€"A cohort study. European Neuropsychopharmacology, 2014, 24, 192-199.	0.3	37
85	Increased exposure to statins in patients developing chronic muscle diseases: a 2-year retrospective study. Annals of the Rheumatic Diseases, 2007, 67, 614-619.	0.5	36
86	Drug interactions between antihypertensive drugs and nonâ€steroidal antiâ€inflammatory agents: a descriptive study using the French Pharmacovigilance database. Fundamental and Clinical Pharmacology, 2014, 28, 230-235.	1.0	36
87	Off-label and unlicensed drug use in children population. Therapie, 2018, 73, 135-149.	0.6	36
88	Vinorelbine-related cardiac events: a meta-analysis of randomized clinical trials. Fundamental and Clinical Pharmacology, 2004, 18, 97-105.	1.0	35
89	Spinal Anesthesia Failure After Local Anesthetic Injection Into Cerebrospinal Fluid. Regional Anesthesia and Pain Medicine, 2011, 36, 322-326.	1.1	35
90	Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients. Expert Opinion on Drug Safety, 2014, 13, 351-360.	1.0	35

#	Article	IF	CITATIONS
91	Disproportionality Analysis for the Assessment of Abuse and Dependence Potential of Pregabalin in the French Pharmacovigilance Database. Clinical Drug Investigation, 2016, 36, 735-742.	1.1	35
92	Use of multiple sources and capture–recapture method to estimate the frequency of hospitalizations related to drug abuse. Pharmacoepidemiology and Drug Safety, 2012, 21, 733-741.	0.9	34
93	The importance of drug–drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France. European Journal of Clinical Pharmacology, 2012, 68, 767-775.	0.8	34
94	Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP®: A Comparison with Classical Methods of Reporting. Drug Safety, 2018, 41, 511-514.	1.4	34
95	Triptan use and risk of cardiovascular events: a nested-case-control study from the French health system database. European Journal of Clinical Pharmacology, 2007, 63, 801-807.	0.8	33
96	QT interval prolongation: prevalence, risk factors and pharmacovigilance data among methadone-treated patients in France. Fundamental and Clinical Pharmacology, 2011, 25, 503-510.	1.0	33
97	Trends of reporting of â€~serious' <i>vs</i> . â€~nonâ€serious' adverse drug reactions over time: a study in the French PharmacoVigilance Database. British Journal of Clinical Pharmacology, 2012, 74, 201-204.	the 1.1	33
98	Neurotological Complications After Radiosurgery Versus Conservative Management in Acoustic Neuromas: A Systematic Review-based Study. Acta Oto-Laryngologica, 2003, 123, 59-64.	0.3	32
99	Adverse Drug Reactions to Local Anaesthetics. Drug Safety, 2009, 32, 345-356.	1.4	32
100	Impact of long-term benzodiazepine use on cognitive functioning in young adults: the VISAT cohort. European Journal of Clinical Pharmacology, 2011, 67, 1045-1052.	0.8	32
101	Antipsychotic Use and Mortality Risk in Community-Dwelling Alzheimer's Disease Patients: Evidence for a Role of Dementia Severity. Current Alzheimer Research, 2012, 9, 1106-1116.	0.7	32
102	Reporting rate of adverse drug reactions to the French pharmacovigilance system with three step 2 analgesic drugs: dextropropoxyphene, tramadol and codeine (in combination with paracetamol). British Journal of Clinical Pharmacology, 2009, 68, 422-426.	1.1	31
103	First French Experience of ADR Reporting by Patients After a Mass Immunization Campaign with Influenza A (H1N1) Pandemic Vaccines. Drug Safety, 2012, 35, 845-854.	1.4	31
104	A European Community Pharmacy-Based Survey to Investigate Patterns of Prescription Fraud through Identification of Falsified Prescriptions. European Addiction Research, 2014, 20, 174-182.	1.3	31
105	A Review of Adverse Outcomes Associated with Psychoactive Drug Use in Nursing Home Residents with Dementia. Drugs and Aging, 2016, 33, 865-888.	1.3	31
106	Doctor shopping of opioid analgesics relative to benzodiazepines: A pharmacoepidemiological study among 11.7 million inhabitants in the French countries. Drug and Alcohol Dependence, 2018, 187, 88-94.	1.6	31
107	Follow-up of Adverse Drug Reactions from Peginterferon alfa-2b–Ribavirin Therapy. Pharmacotherapy, 2004, 24, 1546-1553.	1.2	30
108	HMG CoA Reductase Inhibitors and Impotence. Drug Safety, 2006, 29, 143-149.	1.4	30

#	Article	IF	CITATIONS
109	Does urine drug abuse screening help for managing patients? A systematic review. Drug and Alcohol Dependence, 2014, 136, 11-20.	1.6	30
110	Signal for Thrombosis with Eltrombopag and Romiplostim: A Disproportionality Analysis of Spontaneous Reports Within VigiBase®. Drug Safety, 2015, 38, 1179-1186.	1.4	30
111	Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics. British Journal of Clinical Pharmacology, 2017, 83, 1544-1555.	1.1	30
112	Predictive Factors of Discontinuation and Switch of Cholinesterase Inhibitors in Community-Dwelling Patients with Alzheimer's Disease. CNS Drugs, 2010, 24, 431-442.	2.7	29
113	Drug Prescribing Before and During Pregnancy in South West France. Drug Safety, 2011, 34, 595-604.	1.4	29
114	Drug-induced immune thrombocytopenia: A descriptive survey in the French PharmacoVigilance database. Platelets, 2012, 23, 490-494.	1.1	29
115	A comparative study of adverse drug reactions during two heat waves that occurred in France in 2003 and 2006. Pharmacoepidemiology and Drug Safety, 2012, 21, 285-288.	0.9	29
116	Are adverse drug reaction patterns different between romiplostim and eltrombopag? 2009–2013 French PharmacoVigilance assessment. European Journal of Internal Medicine, 2014, 25, 777-780.	1.0	29
117	Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide populationâ€based study in France. American Journal of Hematology, 2015, 90, 301-305.	2.0	29
118	Is Statin Exposure Associated with Occurrence or Better Outcome in Giant Cell Arteritis? Results from a French Population-based Study. Journal of Rheumatology, 2015, 42, 316-322.	1.0	29
119	An original pharmacoepidemiological–pharmacodynamic method: application to antipsychoticâ€induced movement disorders. British Journal of Clinical Pharmacology, 2017, 83, 612-622.	1.1	29
120	Opiate maintenance with buprenorphine in ambulatory care: a 24-week follow-up study of new users. Drug and Alcohol Dependence, 2003, 72, 297-303.	1.6	28
121	Statin-induced lupus: a case/non-case study in a nationwide pharmacovigilance database. Lupus, 2012, 21, 885-889.	0.8	28
122	Positive predictive values of selected hospital discharge diagnoses to identify infections responsible for hospitalization in the French national hospital database. Pharmacoepidemiology and Drug Safety, 2016, 25, 785-789.	0.9	28
123	Long-term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease. Movement Disorders, 2001, 16, 511-514.	2.2	27
124	Heat-related morbidity in patients with orthostatic hypotension and primary autonomic failure. Movement Disorders, 2005, 20, 1213-1219.	2.2	27
125	Adverse drug reactions in patients older than 70 years during the heat wave occurred in France in summer 2003: a study from the French PharmacoVigilance Database. Pharmacoepidemiology and Drug Safety, 2006, 15, 735-740.	0.9	27
126	Use of Drugs, Tobacco, Alcohol and Illicit Substances in a French Student Population. Therapie, 2012, 67, 429-435.	0.6	27

#	Article	IF	CITATIONS
127	Slow-Release Oral Morphine Sulfate Abuse: Results of the Postmarketing Surveillance Systems for Psychoactive Prescription Drug Abuse in France. European Addiction Research, 2013, 19, 235-244.	1.3	27
128	Gabapentinoid Abuse in France: Evidence on Health Consequences and New Points of Vigilance. Frontiers in Psychiatry, 2021, 12, 639780.	1.3	27
129	Drug utilisation in outpatient children. A comparison among Tenerife, Valencia, and Barcelona (Spain), Toulouse (France), Sofia (Bulgaria), Bratislava (Slovakia) and Smolensk (Russia). European Journal of Clinical Pharmacology, 2004, 60, 127-134.	0.8	26
130	Pregabalin use disorder and secondary nicotine dependence in a woman with no substance abuse history. Therapie, 2016, 71, 575-578.	0.6	26
131	Forged medical prescriptions in a community pharmacy network in Midi-Pyrénées area: assessment of a falsification ratio. European Journal of Clinical Pharmacology, 2002, 57, 911-912.	0.8	25
132	Psychoactive drug consumption: performance-enhancing behaviour and pharmacodependence in workers. Pharmacoepidemiology and Drug Safety, 2005, 14, 81-89.	0.9	25
133	Detection and incidence of muscular adverse drug reactions: a prospective analysis from laboratory signals. European Journal of Clinical Pharmacology, 2004, 60, 285-92.	0.8	24
134	Monitoring of benzodiazepine diversion using a multi-indicator approach. International Clinical Psychopharmacology, 2011, 26, 268-277.	0.9	24
135	Importance of cytochrome P450 (CYP450) in adverse drug reactions due to drug–drug interactions: a PharmacoVigilance study in France. European Journal of Clinical Pharmacology, 2013, 69, 885-888.	0.8	24
136	Predictors of Cardiovascular Hospitalization in Giant Cell Arteritis: Effect of Statin Exposure. A French Population-based Study. Journal of Rheumatology, 2016, 43, 2162-2170.	1.0	24
137	Trends and Patterns of Antidepressant Use in French Children and Adolescents From 2009 to 2016. Journal of Clinical Psychopharmacology, 2018, 38, 327-335.	0.7	24
138	A Pharmacoeconomic Evaluation of Botulinum Toxin in the Treatment of Spasmodic Torticollis. Clinical Neuropharmacology, 2000, 23, 203-207.	0.2	23
139	Ambulatory Medical Assistance - After Cancer (AMA-AC): A model for an early trajectory survivorship survey of lymphoma patients treated with anthracycline-based chemotherapy. BMC Cancer, 2015, 15, 781.	1.1	23
140	Immeasurable time bias due to hospitalization in medicoâ€administrative databases: which impact for pharmacoepidemiological studies?. Pharmacoepidemiology and Drug Safety, 2017, 26, 544-553.	0.9	23
141	Potentially inappropriate prescribing in a population of frail elderly people. International Journal of Clinical Pharmacy, 2017, 39, 113-119.	1.0	23
142	Impact of risk factors on the occurrence of arterial thrombosis and venous thromboembolism in adults with primary immune thrombocytopenia – Results from two nationwide cohorts. Thrombosis Research, 2019, 178, 124-131.	0.8	23
143	Corticosteroid Risk Function of Severe Infection in Primary Immune Thrombocytopenia Adults. A Nationwide Nested Case-Control Study. PLoS ONE, 2015, 10, e0142217.	1.1	23
144	Evolution of drug consumption in a sample of French workers since 1986: the â€~Drugs and Work' study. Pharmacoepidemiology and Drug Safety, 2009, 18, 335-343.	0.9	22

#	Article	IF	CITATIONS
145	Prescribed drugs and violence: a case/noncase study in the French PharmacoVigilance Database. European Journal of Clinical Pharmacology, 2011, 67, 1189-1198.	0.8	22
146	Indicators of Benzodiazepine Use in Nursing Home Residents in France: A Cross-Sectional Study. Journal of the American Medical Directors Association, 2013, 14, 29-33.	1.2	22
147	Positive predictive values of peripheral arterial and venous thrombosis codes in French hospital database. Fundamental and Clinical Pharmacology, 2018, 32, 108-113.	1.0	22
148	Incidence and cost of adverse drug reactions in a French cancer institute. European Journal of Clinical Pharmacology, 1997, 53, 19-22.	0.8	21
149	Drug counselling in pregnancy: an opinion survey of French community pharmacists. Pharmacoepidemiology and Drug Safety, 2004, 13, 711-715.	0.9	21
150	Influence of HCV or HBV coinfection on adverse drug reactions to antiretroviral drugs in HIV patients. European Journal of Clinical Pharmacology, 2006, 62, 243-249.	0.8	21
151	More on the $\hat{a} \in \infty$ Triple Whammy $\hat{a} \in \mathbb{R}$ antihypertensive drugs, non-steroidal anti-inflammatory agents and acute kidney injury $\hat{a} \in \mathbb{R}$ a case/non-case study in the French pharmacovigilance database. Renal Failure, 2014, 36, 1166-1168.	0.8	21
152	Detection and incidence of drug-induced agranulocytosis in hospital: a prospective analysis from laboratory signals. European Journal of Clinical Pharmacology, 2007, 63, 221-228.	0.8	20
153	Healthcare cost impact of biological drugs compared with traditional systemic treatments in psoriasis: a cohort analysis in the French insurance database. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 1235-1244.	1.3	20
154	A 2-Year Prospective Cohort Study of Antidementia Drug Non-Persistency in Mild-to-Moderate Alzheimer's Disease in Europe. CNS Drugs, 2014, 28, 157-170.	2.7	20
155	Pharmacoepidemiology of Immune Thrombocytopenia: Protocols of FAITH and CARMEN Studies. Therapie, 2014, 69, 437-448.	0.6	20
156	Drug Abuse Monitoring: Which Pharmacoepidemiological Resources at the European Level?. Therapie, 2015, 70, 157-165.	0.6	20
157	Effects of a geriatric intervention aiming to improve quality care in nursing homes on benzodiazepine use and discontinuation. British Journal of Clinical Pharmacology, 2016, 81, 759-767.	1.1	20
158	Drug Consumption in Workers in France. Journal of Clinical Epidemiology, 1999, 52, 471-478.	2.4	19
159	Blood Concentrations of Hydroxychloroquine and Its Desethyl Derivative Correlate Negatively with the Percentage of CD45RO+ Cells among CD4+ Lymphocytes in Hydroxychloroquine-Treated Lupus Patients. Annals of the New York Academy of Sciences, 2007, 1108, 41-50.	1.8	19
160	Multimorbidity type, hospitalizations and emergency department visits among nursing home residents: A preliminary study. Journal of Nutrition, Health and Aging, 2014, 18, 705-709.	1.5	19
161	No differences between men and women in adverse drug reactions related to psychotropic drugs: a survey from <scp>F</scp> rance, <scp>I</scp> taly and <scp>S</scp> pain. Fundamental and Clinical Pharmacology, 2014, 28, 342-348.	1.0	19
162	Guideline sheets on the side effects of anticancer drugs are useful for general practitioners. Supportive Care in Cancer, 2015, 23, 3473-3480.	1.0	19

#	Article	IF	Citations
163	Infections in nonâ€splenectomized persistent or chronic primary immune thrombocytopenia adults: risk factors and vaccination effect. Journal of Thrombosis and Haemostasis, 2017, 15, 785-791.	1.9	19
164	Identifying multiple myeloma patients using data from the French health insurance databases. Medicine (United States), 2017, 96, e6189.	0.4	19
165	Association between anticholinergic (atropinic) drug exposure and cognitive function in longitudinal studies among individuals over 50 years old: a systematic review. European Journal of Clinical Pharmacology, 2019, 75, 1631-1644.	0.8	19
166	Tenâ€year trend of opioid and nonopioid analgesic use in the French adult population. British Journal of Clinical Pharmacology, 2021, 87, 555-564.	1.1	19
167	High Maintenance Dosage of Clopidogrel is Associated with a Reduced Risk of Stent Thrombosis in Clopidogrel-Resistant Patients. American Journal of Cardiovascular Drugs, 2010, 10, 29-35.	1.0	18
168	Laboratory Monitoring of Patients Treated with Antihypertensive Drugs and Newly Exposed to Non Steroidal Anti-Inflammatory Drugs: A Cohort Study. PLoS ONE, 2012, 7, e34187.	1.1	18
169	Organizational Factors Associated With Inappropriate Neuroleptic Drug Prescribing in Nursing Homes: A Multilevel Approach. Journal of the American Medical Directors Association, 2015, 16, 590-597.	1.2	18
170	Detection of signals of abuse and dependence applying disproportionality analysis. European Journal of Clinical Pharmacology, 2015, 71, 229-236.	0.8	18
171	Realâ€life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the <scp>French</scp> health insurance database. Pharmacoepidemiology and Drug Safety, 2017, 26, 578-586.	0.9	18
172	Validation of an algorithm identifying incident primary immune thrombocytopenia in the French national health insurance database. European Journal of Haematology, 2017, 99, 344-349.	1.1	18
173	Pharmacogenomics of statin-related myopathy: Meta-analysis of rare variants from whole-exome sequencing. PLoS ONE, 2019, 14, e0218115.	1.1	18
174	Exposure to non-corticosteroid treatments in adult primary immune thrombocytopenia before the chronic phase in the era of thrombopoietin receptor agonists in France. A nationwide population-based study. Autoimmunity Reviews, 2015, 14, 168-173.	2.5	17
175	Drug–drug interactions with imatinib. Medicine (United States), 2016, 95, e5076.	0.4	17
176	Early signal of diverted use of tropicamide eye drops in France. British Journal of Clinical Pharmacology, 2017, 83, 1791-1800.	1.1	17
177	Fear of cancer recurrence in Non- and Hodgkin lymphoma survivors during their first three years of survivorship among French patients. Psychology, Health and Medicine, 2019, 24, 781-787.	1.3	17
178	Was the thrombotic risk of rofecoxib predictible from the French Pharmacovigilance Database before 30 September 2004?. European Journal of Clinical Pharmacology, 2008, 64, 829-834.	0.8	16
179	Interest of large electronic health care databases in addictovigilance: Lessons from 15Âyears of pharmacoepidemiological contribution. Therapie, 2019, 74, 307-314.	0.6	16
180	The value of a health insurance database to conduct pharmacoepidemiological studies in oncology. Therapie, 2019, 74, 279-288.	0.6	16

#	Article	IF	CITATIONS
181	Nicotine Poisoning as a Cause of Cardiac Arrest?. Journal of Toxicology: Clinical Toxicology, 1996, 34, 475-476.	1.5	15
182	Perception of the risk of gastrointestinal adverse drug reactions with non-steroidal anti-inflammatory drugs (including coxibs): differences among general practitioners, gastroenterologists and rheumatologists. European Journal of Clinical Pharmacology, 2003, 59, 685-688.	0.8	15
183	Pharmacological treatment of acute otitis media in children. A comparison among seven locations: Tenerife, Barcelona and Valencia (Spain), Toulouse (France), Smolensk (Russia), Bratislava (Slovakia) and Sofia (Bulgaria). European Journal of Clinical Pharmacology, 2004, 60, 37-43.	0.8	15
184	Drug-Induced Yawning. Drug Safety, 2007, 30, 327-331.	1.4	15
185	Effectiveness of drug tests in outpatients starting opioid substitution therapy. Journal of Substance Abuse Treatment, 2013, 44, 515-521.	1.5	15
186	Comment on: An Insight Into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions. International Journal of Neuropsychopharmacology, 2019, 22, 528-530.	1.0	15
187	Primary Care of Opioid use Disorder: The End of "the French Model�. European Addiction Research, 2020, 26, 346-354.	1.3	15
188	Lack of correlation between the activity of the mesolimbic dopaminergic system and the rewarding properties of pregabalin in mouse. Psychopharmacology, 2019, 236, 2069-2082.	1.5	14
189	Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database. Parkinsonism and Related Disorders, 2020, 70, 55-59.	1.1	14
190	Risk of vaso-occlusive episode after exposure to corticosteroids in patients with sickle cell disease. Blood, 2022, 139, 3771-3777.	0.6	14
191	Valvular heart disease in a patient taking 3,4â€methylenedioxymethamphetamine (MDMA,  Ecstasy'). British Journal of Clinical Pharmacology, 2012, 74, 547-548.	¹ 1.1	13
192	Acute pain management for patients under opioid maintenance treatment. European Journal of Emergency Medicine, 2013, 21, 1.	0.5	13
193	Example of an Investigation of an "Emergent―Phenomenon in Addiction Vigilance: the Case of Methylphenidate. Therapie, 2015, 70, 197-202.	0.6	13
194	Is borderline personality disorder only a mental health problem?. Personality and Mental Health, 2016, 10, 328-336.	0.6	13
195	Identifying cancer drug regimens in French health insurance database: An application in multiple myeloma patients. Pharmacoepidemiology and Drug Safety, 2017, 26, 1492-1499.	0.9	13
196	A comparative study of adverse drug reactions reported through hospital and private medicine. British Journal of Clinical Pharmacology, 1996, 41, 166-168.	1.1	12
197	Drug consumption in a very elderly community-dwelling population. European Journal of Clinical Pharmacology, 2001, 57, 691-692.	0.8	12
198	Drug treatment for diabetes in nursing home residents. Diabetic Medicine, 2014, 31, 570-576.	1.2	12

#	Article	IF	Citations
199	Reducing potentially inappropriate drug prescribing in nursing home residents: effectiveness of a geriatric intervention. British Journal of Clinical Pharmacology, 2018, 84, 1598-1610.	1.1	12
200	Detecting the diverted use of psychoactive drugs by adolescents and young adults: A pilot study. Pharmacoepidemiology and Drug Safety, 2018, 27, 1286-1292.	0.9	12
201	Early Detection of Prescription Drug Abuse Using Doctor Shopping Monitoring From Claims Databases: Illustration From the Experience of the French Addictovigilance Network. Frontiers in Psychiatry, 2021, 12, 640120.	1.3	12
202	Long-term consequences of acute pain for patients under methadone or buprenorphine maintenance treatment. Pain Physician, 2013, 16, E739-47.	0.3	12
203	Exposure to inhibitors of the renin–angiotensin system is a major independent risk factor for acute renal failure induced by sucroseâ€containing intravenous immunoglobulins: a case–control study. Pharmacoepidemiology and Drug Safety, 2012, 21, 314-319.	0.9	11
204	Which Adverse Events Are Related to Health Care during Hospitalization in Elderly Inpatients?. International Journal of Medical Sciences, 2013, 10, 1224-1230.	1.1	11
205	Validation of immune thrombocytopenia diagnosis code in the French hospital electronic database. European Journal of Internal Medicine, 2016, 32, e21-e22.	1.0	11
206	Psychotropic drug initiation during the first diagnosis and the active treatment phase of B cell non-Hodgkinâ \in TM s lymphoma: a cohort study of the French national health insurance database. Supportive Care in Cancer, 2016, 24, 4791-4799.	1.0	11
207	Utilization and costs of HIV antiretroviral drugs in Europe during the last ten years: Impact of generic antiretroviral drugs on cost reduction. Health Policy, 2018, 122, 237-242.	1.4	11
208	β-Adrenoceptor Drugs and Parkinson's Disease: A Nationwide Nested Case–Control Study. CNS Drugs, 2020, 34, 763-772.	2.7	11
209	Multimorbidity type, hospitalizations and emergency department visits among nursing home residents: A preliminary study. Journal of Nutrition, Health and Aging, 2014, 18, 705-9.	1.5	11
210	Medication error caused by confusing drug blisters. Lancet, The, 2004, 363, 2142.	6.3	10
211	Anticholinergics, antimuscarinics or atropinics? About the words in pharmacology. British Journal of Clinical Pharmacology, 2010, 69, 561-562.	1.1	10
212	A questionnaire to document selfâ€medication history in adult patients visiting emergency departments. Pharmacoepidemiology and Drug Safety, 2013, 22, 151-159.	0.9	10
213	Indicators of influenza and pneumococcal vaccination in French nursing home residents in 2011. Vaccine, 2014, 32, 846-851.	1.7	10
214	Comment on: "Social Media Mining for Toxicovigilance: Automatic Monitoring of Prescription Medication Abuse from Twitter". Drug Safety, 2017, 40, 183-185.	1.4	10
215	Infectious risk of biological drugs vs. traditional systemic treatments in moderateâ€toâ€severe psoriasis: a cohort analysis in the French insurance database. Fundamental and Clinical Pharmacology, 2018, 32, 436-449.	1.0	10
216	Interest of pharmacoepidemiology for pharmacodynamics and analysis of the mechanism of action of drugs. Therapie, 2019, 74, 209-214.	0.6	10

#	Article	IF	Citations
217	Epidemiology of autoimmune hemolytic anemia: A nationwide populationâ€based study in <scp>F</scp> rance. American Journal of Hematology, 2021, 96, E291-E293.	2.0	10
218	Warning on increased serious health complications related to non-medical use of nitrous oxide. Therapie, 2021, 76, 478-479.	0.6	10
219	Increase of highâ€risk tramadol use and harmful consequences in France from 2013 to 2018: Evidence from the triangulation of addictovigilance data. British Journal of Clinical Pharmacology, 2022, 88, 3789-3802.	1.1	10
220	Rituximab offâ€label use for immune diseases: assessing adverse events in a singleâ€centre drugâ€utilization survey. British Journal of Clinical Pharmacology, 2008, 66, 320-322.	1.1	9
221	Factors associated with psychoactive drug initiation in a sample of workers in France: results of the VISAT cohort study. Pharmacoepidemiology and Drug Safety, 2010, 19, 296-305.	0.9	9
222	Persistent use of Analgesic Medications in Mild-to-Moderate Alzheimer's Disease. Drugs and Aging, 2013, 30, 439-445.	1.3	9
223	Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review: comment. Journal of Thrombosis and Haemostasis, 2015, 13, 1521-1522.	1.9	9
224	Role of Medicines of Unknown Identity in Adverse Drug Reaction-Related Hospitalizations in Developing Countries: Evidence from a Cross-Sectional Study in a Teaching Hospital in the Lao People's Democratic Republic. Drug Safety, 2017, 40, 809-821.	1.4	9
225	Drug-Induced Dental Caries: A Disproportionality Analysis Using Data from VigiBase. Drug Safety, 2017, 40, 1249-1258.	1.4	9
226	Incremental Costs in Giant Cell Arteritis. Arthritis Care and Research, 2018, 70, 1074-1081.	1.5	9
227	Tamoxifen and the risk of Parkinsonism: a case/non-case study. European Journal of Clinical Pharmacology, 2018, 74, 1181-1184.	0.8	9
228	Cluster Headache in Subjects With Substance Use Disorder: A Case Series and a Review of the Literature. Headache, 2019, 59, 576-589.	1.8	9
229	Significance of antinuclear antibodies in primary immune thrombocytopenia: results of the CARMEN registry. Blood Advances, 2020, 4, 1974-1977.	2.5	9
230	Risk factors of hospitalisation for thrombosis in adults with primary immune thrombocytopenia, including diseaseâ€specific treatments: a French nationwide cohort study. British Journal of Haematology, 2021, 195, 456-465.	1.2	9
231	<p>Assessment of the Accuracy of Using ICD-10 Codes to Identify Systemic Sclerosis</p> . Clinical Epidemiology, 2020, Volume 12, 1355-1359.	1.5	9
232	Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database. BMC Clinical Pharmacology, 2011, 11, 5.	2.5	8
233	A novel approach for medical research on lymphomas. Medicine (United States), 2018, 97, e9418.	0.4	8
234	Tamperâ€resistant prescription forms for narcotics in France: Should we generalize them?. Fundamental and Clinical Pharmacology, 2018, 32, 571-577.	1.0	8

#	Article	IF	Citations
235	Validation of giant cell arteritis diagnosis code in the French hospital electronic database. European Journal of Internal Medicine, 2019, 60, e16-e17.	1.0	8
236	Use of the French healthcare insurance database to estimate the prevalence of exposure to potential drug-drug interactions. European Journal of Clinical Pharmacology, 2020, 76, 1675-1682.	0.8	8
237	Potentially Inappropriate Drug Prescribing in French Nursing Home Residents: An Observational Study. Pharmacy (Basel, Switzerland), 2020, 8, 133.	0.6	8
238	Combatting the misuse of benzodiazepines and related Z drugs in French general practice: a clinical review. BJGP Open, 2020, 4, bjgpopen20X101014.	0.9	8
239	Treatment of acute renal colic in a French emergency department: a comparison of simulated cases and real cases in acute pain assessment and management. European Journal of Clinical Pharmacology, 2001, 57, 685-689.	0.8	7
240	On-Site Drugs of Abuse Urinary Screening Tests for the Management of Opiate-Addicted Patients: A Survey among French General Practitioners. European Addiction Research, 2012, 18, 175-183.	1.3	7
241	The public health benefit of medicines: How it has been assessed in France? The principles and results of five years' experience. Health Policy, 2013, 112, 273-284.	1.4	7
242	Prevalence of pneumococcal vaccination in adult immune thrombocytopenia patients exposed to rituximab or to splenectomy. European Journal of Haematology, 2013, 90, 438-439.	1.1	7
243	Mortality and Antipsychotic Drug Use in Elderly Patients With Parkinson Disease in Nursing Homes. Journal of the American Medical Directors Association, 2017, 18, 791-796.	1.2	7
244	Psychiatric disorders as predictors of long-term opioid therapy and the need for treating chronic pain correctly in patients with prior opioid substance use disorder: a commentary. Pain, 2017, 158, 6-7.	2.0	7
245	Cross-national health care database utilization between Spain and France: results from the EPICHRONIC study assessing the prevalence of type 2 diabetes mellitus. Clinical Epidemiology, 2018, Volume 10, 863-874.	1.5	7
246	Parkinsonism Associated with Gabapentinoid Drugs: A Pharmacoepidemiologic Study. Movement Disorders, 2020, 35, 176-180.	2,2	7
247	Validation of hemolytic anemia discharge diagnosis codes in the French hospital database. European Journal of Internal Medicine, 2020, 79, 136-138.	1.0	7
248	Psychotropic drug initiation in patients diagnosed with chronic myeloid leukemia: a populationâ€based study in France. Fundamental and Clinical Pharmacology, 2020, 34, 612-622.	1.0	7
249	Evolution of doctor shopping for oxycodone in the 67 million inhabitants in France as a proxy for potential misuse or abuse. Pain, 2021, 162, 770-777.	2.0	7
250	A Prospective Intensive Study of Adverse Drug Reactions in Urban General Practice. Clinical Drug Investigation, 1995, 10, 117-122.	1.1	6
251	A Comparative Survey of Antidepressant Drug Prescribing Habits of General Practitioners and Psychiatrists. Clinical Drug Investigation, 1998, 16, 53-61.	1.1	6
252	Use of Codeine and Non-Codeine Cough Suppressants. Clinical Drug Investigation, 2002, 22, 399-402.	1.1	6

#	Article	IF	Citations
253	The Nursing Home Effect: A Case Study of Residents With Potential Dementia and Emergency Department Visits. Journal of the American Medical Directors Association, 2013, 14, 901-905.	1.2	6
254	Trends in opioid analgesics use in Europe: a ten-year perspective. Clinical Therapeutics, 2015, 37, e4.	1.1	6
255	Sex and age differences in ED patients with mental and behavioral disorders due to psychoactive substance use. American Journal of Emergency Medicine, 2015, 33, 1612-1616.	0.7	6
256	Comparison of adherence to generic multiâ€ŧablet regimens vs. brand multiâ€ŧablet and brand singleâ€ŧablet regimens likely to incorporate generic antiretroviral drugs by breaking or not fixedâ€dose combinations in HIVâ€infected patients. Fundamental and Clinical Pharmacology, 2018, 32, 450-458.	1.0	6
257	Trends of atropinic (anticholinergic) exposure in the elderly: a 10â€year analysis in the French EGB database. Fundamental and Clinical Pharmacology, 2019, 33, 471-478.	1.0	6
258	Adverse drug reactions in infants, children and adolescents exposed to antidepressants: a French pharmacovigilance study. European Journal of Clinical Pharmacology, 2020, 76, 1591-1599.	0.8	6
259	Development and Validation of a Model to Identify Alzheimer's Disease and Related Syndromes in Administrative Data. Current Alzheimer Research, 2021, 18, 142-156.	0.7	6
260	Patterns of Tyrosine Kinase Inhibitor Utilization in Newly Treated Patients With Chronic Myeloid Leukemia: An Exhaustive Population-Based Study in France. Frontiers in Oncology, 2021, 11, 675609.	1.3	6
261	The challenges of pharmacoepidemiology of orphan drugs in rare diseases. Therapie, 2020, 75, 215-220.	0.6	6
262	Risk of pacemaker implantation after radiotherapy for breast cancer: A study based on French nationwide health care database sample. IJC Heart and Vasculature, 2022, 38, 100936.	0.6	6
263	Efficacy of Psychoeducational Intervention on Allograft Function in Kidney Transplant Patients: 10-Year Results of a Prospective Randomized Study. Experimental and Clinical Transplantation, 2016, 14, 38-44.	0.2	6
264	Naloxone does not prevent apomorphine-induced emesis or hypotension in dogs. Clinical Autonomic Research, 1994, 4, 303-305.	1.4	5
265	Fertility and outcomes of pregnancy after chemotherapy in a sample of childbearing aged women. Fundamental and Clinical Pharmacology, 2004, 18, 573-579.	1.0	5
266	Modifications of Low-Molecular Weight Heparin Use in a French University Hospital after Implementation of New Guidelines. Drug Safety, 2007, 30, 409-417.	1.4	5
267	Prescribers' indications for drugs in childhood: A survey of five European countries (Spain, France,) Tj ETQq1 1 0.7 1784-1790.	84314 rgB 0.7	BT /Overlo <mark>ck</mark> 5
268	Utilisation de la méthode capture-recapture pour l'évaluation de la fréquence des effets indésirables « graves » médicamenteux : l'expérience du CHU de Toulouse. Bulletin De L'Academie Nationale De Medecine, 2008, 192, 421-431.	0.0	5
269	Pharmacoepidemiology Studies: what Levels of Evidence and how can They be Reached?. Therapie, 2013, 68, 247-252.	0.6	5
270	Population awareness of risks related to medicinal product use in Vientiane Capital, Lao PDR: a cross-sectional study for public health improvement in low and middle income countries. BMC Public Health, 2015, 15, 590.	1.2	5

#	Article	IF	Citations
271	Phone-based safety monitoring of the first year of baclofen treatment for alcohol use disorder: the BACLOPHONE cohort study protocol. Expert Opinion on Drug Safety, 2017, 16, 1-8.	1.0	5
272	Study protocol of the ESUB-MG cluster randomized trial: a pragmatic trial assessing the implementation of urine drug screening in general practice for buprenorphine maintained patients. BMC Family Practice, 2016, 17, 24.	2.9	5
273	Effect of dementia on receipt of influenza vaccine: a cohort study in French older adults using administrative data: 2007à€"2012. Fundamental and Clinical Pharmacology, 2017, 31, 471-480.	1.0	5
274	Use of French healthcare insurance databases in pediatric pharmacoepidemiology. Therapie, 2018, 73, 127-133.	0.6	5
275	Analgesic Drug Prescription After Carpal Tunnel Surgery. Regional Anesthesia and Pain Medicine, 2018, 43, 19-24.	1.1	5
276	Considering sex-specific adverse drug reactions should be a priority in pharmacovigilance and pharmacoepidemiological studies. EClinicalMedicine, 2019, 17, 100216.	3.2	5
277	Benzodiazepine exposure in subjects with incident Alzheimer's disease and related syndromes in France: a longitudinal study 2011–2017. International Clinical Psychopharmacology, 2020, 35, 270-278.	0.9	5
278	Drugâ€induced tics: An observational postmarketing study. Human Psychopharmacology, 2020, 35, e2734.	0.7	5
279	A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007–2019). Drug Safety, 2022, 45, 37-44.	1.4	5
280	Cannabinoid-Related Acute Pancreatitis: An Update from International Literature and Individual Case Safety Reports. Drug Safety, 2022, 45, 215-235.	1.4	5
281	Risk of Immune Thrombocytopenia After Influenza Vaccine. JAMA Internal Medicine, 2022, 182, 444.	2.6	5
282	Study on the Regular Use of Drugs in Workers over 50 Years of Age. Clinical Drug Investigation, 1995, 9, 1-7.	1.1	4
283	Mortality Rates Among Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors: Comment on the Article by Simard et al. Arthritis and Rheumatism, 2013, 65, 1670-1671.	6.7	4
284	Dépistage des troubles de la personnalité avec la version française du Personality Diagnostic Questionnaire-4+ dans une population psychiatriqueÂ: une étude préliminaire. Annales Medico-Psychologiques, 2016, 174, 39-44.	0.2	4
285	Identification of Somatic Disorders Related to Psychoactive Drug Use from an Inpatient Database in a French University Hospital. Clinical Drug Investigation, 2018, 38, 977-982.	1.1	4
286	Additional Costs of Polymyalgia Rheumatica With Giant Cell Arteritis. Arthritis Care and Research, 2019, 71, 1127-1131.	1.5	4
287	Is there overuse of proton pump inhibitors in Bâ€cell nonâ€Hodgkin lymphomas? A cohort study based on the French health insurance database in the Midiâ€Pyrénées region. Fundamental and Clinical Pharmacology, 2019, 33, 327-338.	1.0	4
288	Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France. Journal of Medical Economics, 2020, 23, 235-242.	1.0	4

#	Article	IF	Citations
289	Le psychotraumatisme chez l'enfant et l'adolescentÂ: donnés actuelles et perspectives. Neuropsychiatrie De L'Enfance Et De L'Adolescence, 2020, 68, 384-393.	0.1	4
290	Benzodiazepine Dispensing to Persons With Dementia in France, 2011-2016: A Nationwide Study. Journal of the American Medical Directors Association, 2020, 21, 830-836.	1.2	4
291	Perceived risk of opioid use disorder secondary to opioid analgesic medication use by the general population in France. European Journal of Pain, 2022, 26, 729-739.	1.4	4
292	Risk of gastrointestinal haemorrhage with calcium antagonists. British Journal of Clinical Pharmacology, 1998, 46, 88-9.	1.1	4
293	Association between NMDAR antagonists, drug abuse and dependence: A disproportionality analysis from the WHO pharmacovigilance database. British Journal of Clinical Pharmacology, 2022, 88, 4937-4940.	1.1	4
294	Drugs and Cancer: an Analysis of the French Pharmacovigilance Database. Therapie, 2013, 68, 149-154.	0.6	3
295	Factors affecting chronic pain and increases of analgesic drug consumption after knee arthroplasty. Pain, 2014, 155, 2720-2721.	2.0	3
296	From rural to urban areas: differences in behavioural and psychological symptoms of dementia in nursing home residents according to geographical location. Psychogeriatrics, 2014, 14, 229-234.	0.6	3
297	Dementia Diagnosis and Influenza Vaccination in French Nursing Home Residents. Journal of the American Geriatrics Society, 2015, 63, 1256-1258.	1.3	3
298	Analgesic Drug Consumption Increases After Carpal Tunnel Surgery: A Pharmacoepidemiological Study Investigating Postoperative Pain. Clinical Therapeutics, 2015, 37, e64-e65.	1.1	3
299	Misuse of Benzodiazepines in France. , 2016, , 1101-1111.		3
300	Impact of pregnancy on psychoactive substance use among women with substance use disorders recruited in addiction specialized care centers in France. Fundamental and Clinical Pharmacology, 2018, 32, 188-197.	1.0	3
301	Cardiovascular risk factors in immune thrombocytopenia adults: Results from the CARMEN registry. American Journal of Hematology, 2018, 93, E181-E184.	2.0	3
302	Identification and tracking of addictovigilance signals in general practice: which interactions between the general practitioners and the French addictovigilance network?. Fundamental and Clinical Pharmacology, 2018, 32, 641-642.	1.0	3
303	Vaccination during the First Diagnosis of Multiple Myeloma: A Cohort Study of the French National Health Insurance Database. Vaccines, 2020, 8, 722.	2.1	3
304	Use of the French national health insurance information system for research in the field of mental health: Systematic review and perspectives. Fundamental and Clinical Pharmacology, 2022, 36, 16-34.	1.0	3
305	Correspondence on $\hat{a}\in \mathbb{R}$ isk of systemic lupus erythematosus after immune thrombocytopenia and autoimmune haemolytic anaemia: a nationwide French study $\hat{a}\in \mathbb{N}$. Annals of the Rheumatic Diseases, 2023, 82, e95-e95.	0.5	3
306	Clinical Epidemiology and First-Line Treatment in Immune Thrombocytopenia Adults. Results of the Carmen Prospective Cohort. Blood, 2015, 126, 3473-3473.	0.6	3

#	Article	IF	CITATIONS
307	Dermatological adverse drug reactions of anticancer drugs: International data of pharmacovigilance: VigiBase®. Therapie, 2022, 77, 219-227.	0.6	3
308	Weak Opioid Analgesics Abuse and Addiction. , 2016, , 375-391.		2
309	Pretreatment with standardâ€dose intravenous methylprednisolone does not improve outcomes in newly diagnosed immune thrombocytopenia (<scp>ITP</scp>). European Journal of Haematology, 2018, 100, 412-418.	1.1	2
310	Impact of a geriatric intervention conducted in nursing homes on inappropriate prescriptions of antipsychotics. European Geriatric Medicine, 2019, 10, 285-293.	1.2	2
311	Case Report: the Comorbidity of Pregabalin-Use Disorder and Post-Traumatic Stress Disorder: Clinical and Pharmacological Issues. International Journal of Mental Health and Addiction, 2022, 20, 152-161.	4.4	2
312	Antidepressant Use and Progression of Mild to Moderate Alzheimer's Disease: Results from the European ICTUS Cohort. Journal of the American Medical Directors Association, 2021, 22, 433-439.	1.2	2
313	Evolution of medication consumption in a working environment in France: Results of the four waves of the "Drugs and Work―study (1986–2016). Pharmacoepidemiology and Drug Safety, 2021, 30, 661-668.	0.9	2
314	Medical prescription forms of opioid cough suppressants falsified by the patients before and after they switched from overâ€theâ€counter to prescriptionâ€only in France. British Journal of Clinical Pharmacology, 2022, 88, 1713-1721.	1.1	2
315	Risk Factors of Thrombosis in Adults with Primary Immune Thrombocytopenia. a French Nationwide Cohort Study. Blood, 2018, 132, 3745-3745.	0.6	2
316	Eltrombopag for Immune Thrombocytopenia Adult Patients in the Real-Life Practice in France. Interim Results of the Elextra Study. Blood, 2019, 134, 2372-2372.	0.6	2
317	Eltrombopag for Immune Thrombocytopenia in Adult Patients in the Real-World in France. Final Results of the Elextra Study. Blood, 2020, 136, 11-12.	0.6	2
318	Incident users of tyrosine kinase inhibitors in patients with chronic myeloid leukemia: Analysis of anticancer treatment trajectories—A French populationâ€based study using the French national health data system. American Journal of Hematology, 2022, 97, .	2.0	2
319	Coxibs: evolution of prescription's behaviour in France. Fundamental and Clinical Pharmacology, 2007, 21, 317-325.	1.0	1
320	Did thirstâ€blockers contribute to the exorbitant number of fatalities during the French 2003 heat wave?. Pharmacoepidemiology and Drug Safety, 2008, 17, 312-313.	0.9	1
321	Safety of amide local anesthetics: new trends. Expert Opinion on Drug Safety, 2010, 9, 759-769.	1.0	1
322	THU0283â€Incremental Costs of Giant Cell Arteritis in France. Annals of the Rheumatic Diseases, 2015, 74, 298.3-298.	0.5	1
323	Triptan Use and Serious Cardiovascular Events In Elderly Over 65 Years In France: A Nationwide Retrospective Propensity-Matched Cohort Study. Clinical Therapeutics, 2017, 39, e33.	1.1	1
324	Generic antiretroviral drug use in HIV-infected patients: A cohort study from the French health insurance database. Therapie, 2018, 73, 257-266.	0.6	1

#	Article	IF	CITATIONS
325	Non-cancer drug consumption during the early trajectory of lymphoma survivorship. Therapie, 2018, 73, 307-317.	0.6	1
326	Novel forms of injectable buprenorphine and French model of opioid use disorder treatment. Therapie, 2020, 75, 393-395.	0.6	1
327	Evaluation of Prescription Practices of Domperidone in Parkinson's Disease: A Cross Sectional Study Among French Neurologists. CNS Drugs, 2020, 34, 1267-1274.	2.7	1
328	Potential inappropriate use of strong opioid analgesics in cancer outpatients during the last year of life in France and associated factors. British Journal of Clinical Pharmacology, 2022, 88, 1691-1703.	1.1	1
329	Qu'est-ce que la pharmacoépidémiologie?. Bulletin De L'Academie Nationale De Medecine, 2015, 199, 263-273.	0.0	1
330	Validation of an Algorithm Identifying Incident Primary Immune Thrombocytopenia in the French National Health Insurance Database. Blood, 2016, 128, 4764-4764.	0.6	1
331	The effect of an ambulatory medical assistance during chemotherapy and follow-up among patient with diffuse large B-cell lymphoma on treatment adherence Journal of Clinical Oncology, 2014, 32, e19550-e19550.	0.8	1
332	Le point sur les cas d'abus et de dépendance à la poudre d'opium (Lamaline®, Izalgi®) en France. Douleur Et Analgesie, 2019, 32, 95-98.	0.2	1
333	The cardiovascular health of prisoners who use cannabis: An exploratory study among hospitalised prisoners. Therapie, 2020, 75, 579-589.	0.6	1
334	Risk of bleeding associated with nonsteroidal antiâ€inflammatory drug use in patients exposed to antithrombotic therapy: a caseâ€crossover study. Journal of Clinical Pharmacology, 2021, , .	1.0	1
335	Patterns of opioid analgesic prescribing in cancer outpatients during the last year of life in France: A pharmacoepidemiological cohort study based on the French health insurance database. Therapie, 2022, 77, 703-711.	0.6	1
336	Supervised prescription of methadone plus heroin is more effective than methadone alone. Evidence-Based Healthcare and Public Health, 2004, 8, 110-111.	0.0	0
337	Affinité sérotoninergique 5HT2 C et diabà te médicamenteuxÂ: étude de pharmacoépidémiologie da base de pharmacoVigilance de l'OMS. European Psychiatry, 2013, 28, 106-106.	ans la 0.1	0
338	Factors affecting chronic pain and increases of analgesic drug consumption after knee arthroplasty: Reply. Pain, 2014, 155, 2721-2722.	2.0	0
339	Infectious risk of biological drugs versus conventional systemic treatments in moderate to severe psoriasis. Clinical Therapeutics, 2015, 37, e4.	1.1	0
340	Thomboprophylaxis In Multiple Myeloma Patients Treated With Lenalidomide or Thalidomide. Clinical Therapeutics, 2015, 37, e65.	1.1	0
341	Outpatient Antibiotic Prescriptions with High Risk of Bacterial Resistance in France: A National Healthcare Insurance Database Analysis. Clinical Therapeutics, 2017, 39, e12.	1.1	0
342	Searching Hospital Database for Detecting the Serious Consequences Related to Use of Drugs With an Abuse Potential. Clinical Therapeutics, 2017, 39, e91.	1.1	0

#	Article	lF	Citations
343	AB0565â€Insufficient influenza vaccination coverage in giant cell arteritis. a french population-based study., 2017,,.		O
344	Costs of Hodgkin and Non-Hodgkin Lymphoma in France: Results on the Basis of the French National Health Insurance Database. Value in Health, 2018, 21, S25.	0.1	O
345	Teaching Basic Knowledge on Substance Use Disorders: The Impact of e-Learning on Health Professionals. Clinical Therapeutics, 2019, 41, 2154-2161.	1.1	O
346	No increased risk of cataract in adult patients with primary immune thrombocytopenia treated with eltrombopag. A French nationwide nested caseâ€control study. British Journal of Haematology, 2020, 189, e137-e140.	1.2	0
347	Reply to: Comment on "Parkinsonism Associated with Gabapentinoid Drugs: A Pharmacoepidemiological Study― Movement Disorders, 2020, 35, 376-377.	2.2	O
348	Bacterial infections in people who inject psychoactive substances: An observational study in a French university hospital. A comment. Therapie, 2021, 76, 525-526.	0.6	O
349	Exposure to Corticoid-Sparing Treatments in Adult Primary Immune Thrombocytopenia before the Chronic Phase in the Era of Thrombopoietin Receptor Agonists in France. a Nationwide Population-Based Study. Blood, 2014, 124, 2178-2178.	0.6	O
350	Incidence of Adverse Drug Reactions Related to Immune Thrombocytopenia Drugs. A Prospective Cohort Study. Blood, 2015, 126, 1056-1056.	0.6	0
351	Quelle PharmacoVigilance pour les vaccins ?. Bulletin De L'Academie Nationale De Medecine, 2016, 200, 241-250.	0.0	O
352	Interest in Initiating Corticosteroids By Intravenous Methylprednisolone at Standard Dose in Newly Diagnosed Immune Thrombocytopenia Adults: Results of the Prospective Carmen Registry. Blood, 2016, 128, 3736-3736.	0.6	0
353	Positivity Rates of Tests Used at Immune Thrombocytopenia Diagnosis to Detect Associated Diseases. a Prospective Multicenter Cohort Study of 218 Patients. Blood, 2016, 128, 1367-1367.	0.6	O
354	Drug Use and Mortality in Parkinson Disease. Journal of the American Medical Directors Association, 2017, 18, 989.	1.2	O
355	Risk of Vaccine-Induced Immune Thrombocytopenia in Children. Nationwide Case Cross-over and Self-Controlled Case Series Studies in France. Blood, 2018, 132, 738-738.	0.6	O
356	Positivity Rate of Systematic Bone Marrow Smear Above 60-Year-Old Patients with Newly Diagnosed Immune Thrombocytopenia to Screen for Associated Hematological Malignancy. Results from the French Prospective Multicenter Carmen Registry. Blood, 2019, 134, 1083-1083.	0.6	0
357	Validation of Hemolytic Anemia Codes in the French Hospital Database. Blood, 2019, 134, 3460-3460.	0.6	O
358	Risk of Immune Thrombocytopenia Induced By Influenza Vaccine. a Nationwide Population-Based Study in France. Blood, 2019, 134, 1086-1086.	0.6	0
359	No Increased Risk of Cataract in Immune Thrombocytopenia Adult Patients Treated with Eltrombopag. a French Nationwide Nested Case-Control Study. Blood, 2019, 134, 2363-2363.	0.6	0
360	Cannabis et pathologies cardio-vasculaires. La Presse Médicale Formation, 2020, 1, 355-363.	0.1	0

#	Article	IF	CITATIONS
361	Autoimmune Hemolytic Anemia: A Disease of the Elderly and the Very Elderly with Increased Mortality and Increased Rates of Hospitalization for Thrombosis and Infection. Blood, 2020, 136, 41-41.	0.6	0
362	Impact of the treatment of chronic myeloid leukaemia by tyrosine-kinase inhibitors on sick leaves refund: a nationwide cohort study. Supportive Care in Cancer, 2022, , 1.	1.0	0